New data indicates that retatrutide, a dual-action medication, could represent a significant advance in body reduction . This drug combines the properties of a GLP-1 agonist and a GIP receptor , possibly offering a enhanced outcome than current therapies . Clinical trials have shown positive results , including considerable declines in size and ad